GameChangers: Paxlovid in COVID-19 Vaccinated Patients
GameChangers: Paxlovid in COVID-19 Vaccinated Patients
Join us as we explore new trial data examining Paxlovid’s effectiveness in high-risk, vaccinated patients.
GameChanger: Significantly high-risk patients are still at risk from active Covid-19 infection. A new trial looks at Paxlovid use in high-risk, vaccinated patients.
Upon successful completion of this course, learners should be able to:
1. Discuss EPIC SR study findings.
2. Describe benefits of Paxlovid for specific patient groups based on trial data.
Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences
Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.
Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: May 13, 2024
Planned Expiration Date: May 13, 2025
Copyright 2024, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.
CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.
¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.
Additional information
| Duration | 0h 30m |
|---|---|
| Topic Designator | Disease State/Drug Therapy |
| ACPE | Yes |
| ACPE Topic | 01 Drug Therapy |
| Role | Pharmacist |
| Media-Type | Podcast |
| Release Date | 5/13/24 |
| CEUs | 0.05 |
| Rating | 4 |
| ACPE Number | 0107-0000-24-172-H01-P |
